Lipella Pharmaceuticals Inc. (LIPO) News
Filter LIPO News Items
LIPO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest LIPO News From Around the Web
Below are the latest news stories about LIPELLA PHARMACEUTICALS INC that investors may wish to consider to help them evaluate LIPO as an investment opportunity.
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host DiseaseLipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in Pittsburgh, PA, announced today that it has been granted "Orphan Drug Designation" from the U.S. Food and Drug Administration (FDA) for its drug candidate, LP-310, which has been designed for the treatment of oral Graft-versus-Host Disease (GvHD). |
Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the closing of its previously announced private placement transaction, priced at-the-market under Nasdaq rules, for the purchase and sale of pre-funded warrants to purchase up to an aggregate of 1,315,790 shares and warrants to purchase up to an aggregate of 1,315,790 shares. The purchase price for |
Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq RulesLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our," "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced the entry, on October 23, 2023, into definitive agreements for the purchase and sale, in a private placement transaction priced at-the-market under Nasdaq rules, of pre-funded warrants to purchase up to an aggregate of 1,315,790 shares and warrants to purchase up to an aggregate of 1,315,790 shares |
Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo ConferencePITTSBURGH, PA / ACCESSWIRE / October 23, 2023 / Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, will present at the ... |
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen PlanusLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the U.S. Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application for a multi-center, phase-2a, dose-escalation clinical trial to assess the safety and efficacy of LP-310 in patients with symptomatic oral lichen planus (OLP), a highly morbid condition with n |
Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and NephrologyLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announces that the results of its successful Phase 2a clinical trial have been the published in the peer-reviewed Journal of Urology and Nephrology. |
Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for ShareholdersNEW YORK, NY - (NewMediaWire) - June 13, 2023 - PCG Digital--Lipella Pharmaceuticals (Nasdaq: LIPO) is a clinical-stage biotechnology company addressing serious diseases with significant unmet medical need and potentially changing the lives of countl... |
Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate UpdateLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today provides a corporate update and announces its first quarter 2023 financial results. |
Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022)Lipella Pharmaceuticals ( NASDAQ:LIPO ) First Quarter 2023 Results Key Financial Results Net loss: US$1.07m (loss... |
Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual MeetingLipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has delivered a late-breaking presentation at the annual meeting of the American Urological Association (AUA) Annual Meeting in Chicago on April 30, 2023. |